We Approach the Treatment of Autoimmune Diseases Differently
At AnTolRx we are approaching the treatment of autoimmune diseases differently–through the development of novel nanoparticle-based therapies to promote antigen-specific immune tolerance. Standard therapies broadly suppress the immune system, inducing side effects that may include life threatening infections and tumors. Thus, there is an unmet clinical need for methods of targeted immune-regulation. Our proprietary drug development approach selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases.
Our lead program addresses significant unmet needs in the field of Type 1 Diabetes through the development of novel patented therapies for treatment of disease.
Our therapies are designed to selectively target pathogenic T cells through the delivery of both a self-antigen and an endogenous tolerogenic molecule which induces an anti-inflammatory phenotype. It has shown significant therapeutic effects in pre-clinical models of Type 1 Diabetes and has the potential to provide an efficacy and safety profile unlike any other treatment currently available.